Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir in treatment-naive HIV
NCT04143594Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of lenacapavir in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 54. Started Nov 2019; status: completed.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04143594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143594.